Pablo Stiefel García-Junco

Prof. Dr. Pablo Stiefel García-Junco

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2012 in American Journal of Hypertension
Verified
Journal Article
Open access
PDF file
RMRafael Moreno-Luna
Rafael Moreno-Luna
RMRocio Muñoz-Hernandez
Rocio Muñoz-Hernandez
MMMaria L. Miranda
Maria L. Miranda
ACAlzenira F. Costa
Alzenira F. Costa
LJLuis Jimenez-Jimenez
Luis Jimenez-Jimenez
PGPablo Stiefel García-Junco
Pablo Stiefel García-Junco
Background. Olive oil polyphenols have been associated with several cardiovascular health benefits. This study aims to examine the influence of a polyp

8 October 2013 in American Journal of Hypertension
Verified
Journal Article
Open access
PDF file
MMMaria L. Miranda
Maria L. Miranda
HMHada C. Macher
Hada C. Macher
RMRocio Muñoz-Hernández
Rocio Muñoz-Hernández
AVAntonio Vallejo-Vaz
Antonio Vallejo-Vaz
RMRafael Moreno-Luna
Rafael Moreno-Luna
PGPablo Stiefel García-Junco
Pablo Stiefel García-Junco
Increased plasma levels of circulating cell-free DNA (c-f DNA) have been recently described in diseases related to ischemia and/or hypoxia. Preeclampsia (PCL) is a hypertensive disorder of pregnancy, of unknown origin, where a defective placentation resulting in placental ischemia plays an important role. HELLP syndrome (haemolysis, elevated liver enzymes, and low platelet count) is the most serious form of PCL. The origin of the disease is unknown, and there are no markers to help us to make an early diagnosis of disease or to predict patients who are at risk of suffering serious complications. We measured circulating c-f DNA levels in a group of control pregnant women (n = 20), patients with mild PCL (n = 9), patients with severe PCL (n = 24), and patients with HELLP syndrome (n = 8). Values of circulating c-f DNA were 333.59±64.3ng/ml in control subjects; 635.11±111.7ng/ml in patients with mild PCL; 1,264.63±127.1ng/ml in patients with severe PCL, and 1,595.95±269.8ng/ml in patients with HELPP syndrome. (P < 0.0001). Values of c-f DNA >950ng/ml had a sensitivity and specificity for detecting severe PCL and/or HELLLP syndrome of 0.71 and 0.93, respectively. As far as we know, this is the first report of increased c-f DNA levels in HELLP syndrome. In this preliminary report, we have observed a gradual and strong relation between c-f DNA levels and range of severity of PCL, with it the highest in patients with HELLP syndrome. Further studies are needed for evaluating the utility of this technique in hypertensive disorders of pregnancy and, particularly, in HELLP syndrome.

1 January 2011 in International Journal of Hypertension
Verified
Journal Article
Open access
PDF file
PGPablo Stiefel García-Junco
Pablo Stiefel García-Junco
AVAntonio Vallejo-Vaz
Antonio Vallejo-Vaz
SMS. García Morillo
S. García Morillo
JVJ. Villar
J. Villar
Aldosterone facilitates cardiovascular damage by increasing blood pressure and through different mechanisms that are independent of its effects on blood pressure. In this respect, recent evidence involves aldosterone in the pathogenesis of metabolic syndrome. Although this relationship is complex, there is some evidence suggesting that different factors may play an important role, such as insulin resistance, renin-angiotensin-aldosterone system, oxidative stress, sodium retention, increased sympathetic activity, levels of free fatty acids, or inflammatory cytokines and adipokines. In addition to the classical pathway by which aldosterone acts through the mineralocorticoid receptors leading to sodium retention, aldosterone also has other mechanisms that influence cardiovascular tissue remodelling. Finally, overweight and obesity promote the adrenal secretion of aldosterone, increasing the predisposition to type 2 diabetes mellitus. Further studies are needed to better establish therapeutic strategies that act on the blockade of mineralocorticoid receptor in the treatment and prevention of cardiovascular diseases related to the excess of aldosterone and the metabolic syndrome.

27 March 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RMRocio Muñoz-Hernandez
Rocio Muñoz-Hernandez
AVAntonio Vallejo-Vaz
Antonio Vallejo-Vaz
AAAngeles Sanchez Armengol
Angeles Sanchez Armengol
RMRafael Moreno-Luna
Rafael Moreno-Luna
CCCandela Caballero-Eraso
Candela Caballero-Eraso
PGPablo Stiefel García-Junco
Pablo Stiefel García-Junco
This study tries to assess the endothelial function in vivo using flow-mediated dilatation (FMD) and several biomarkers of endothelium formation/restoration and damage in patients with obstructive sleep apnoea (OSA) syndrome at baseline and after three months with CPAP therapy. Observational study, before and after CPAP therapy. We studied 30 patients with apnoea/hypopnoea index (AHI) >15/h that were compared with themselves after three months of CPAP therapy. FMD was assessed non-invasively in vivo using the Laser-Doppler flowmetry. Circulating cell-free DNA (cf-DNA) and microparticles (MPs) were measured as markers of endothelial damage and the vascular endothelial growth factor (VEGF) was determined as a marker of endothelial restoration process. After three month with CPAP, FMD significantly increased (1072.26 ± 483.21 vs. 1604.38 ± 915.69 PU, p< 0.005) cf-DNA and MPs significantly decreased (187.93 ± 115.81 vs. 121.28 ± 78.98 pg/ml, p<0.01, and 69.60 ± 62.60 vs. 39.82 ± 22.14 U/μL, p<0.05, respectively) and VEGF levels increased (585.02 ± 246.06 vs. 641.11 ± 212.69 pg/ml, p<0.05). These changes were higher in patients with more severe disease. There was a relationship between markers of damage (r = -0.53, p<0.005) but not between markers of damage and restoration, thus suggesting that both types of markers should be measured together. CPAP therapy improves FMD. This improvement may be related to an increase of endothelial restoration process and a decrease of endothelial damage.

1 August 2013 in Archives of Medical Research
Verified
Journal Article
Closed access
PGPablo Stiefel García-Junco
Pablo Stiefel García-Junco
MSMaria Angeles Sánchez-Armengol
Maria Angeles Sánchez-Armengol
JVJosé Villar
José Villar
AVAntonio Vallejo-Vaz
Antonio Vallejo-Vaz
RMRafael Moreno-Luna
Rafael Moreno-Luna
FCFrancisco Capote
Francisco Capote

1 November 2009 in Medicina Clinica
Verified
Journal Article
Closed access
PGPablo Stiefel García-Junco
Pablo Stiefel García-Junco
MMMaría Luisa Miranda
María Luisa Miranda
LBLola M. Bellido
Lola M. Bellido
JLJerónimo Luna
Jerónimo Luna
LJLuis Jiménez
Luis Jiménez
JVJosé Villar
José Villar